

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

REGENERON PHARMACEUTICALS, INC.

Petitioner,

v.


NOVARTIS PHARMA AG,
NOVARTIS TECHNOLOGY LLC,
NOVARTIS PHARMACEUTICALS CORPORATION,
Patent Owner

Case No. IPR2021-00816

U.S. Patent No. 9,220,631

DECLARATION OF JAMES AGALLOCO

TABLE OF CONTENTS

	Page
I. INTRODUCTION	1
II. QUALIFICATIONS AND COMPENSATION.....	1
III. LEGAL STANDARDS	5
IV. A PERSON OF ORDINARY SKILL IN THE ART	7
V. DEFINITION OF “TERMINAL STERILIZATION” IN THE '631 PATENT.....	8
VI. BACKGROUND	9
A. Sterilization of Pre-filled Syringes.....	9
B. Sterility Assurance and Validation.....	12
VII. RELEVANT PRIOR ART TO THE '631 PATENT.....	18
A. “Sigg” – WO 2011/006877	18
B. “Lam” – WO 2008/077155	19
VIII. A Person with Specialized Skills in Microbiology Would Be Motivated to Use Sigg’s VHP Method to Achieve an SAL of 10^{-6} and Would Have a Reasonable Expectation of Success in so Doing.....	21
A. Sigg Provides a Motivation to Use its VHP Method	21
B. A Person with Specialized Skills in Microbiology Would Understand that Sigg’s VHP Method Could Be Used to Achieve an SAL of 10^{-6}	23
C. A Person with Specialized Skills in Microbiology Would Have Reasonably Expected to Succeed in Using Sigg’s VHP Method to Achieve an SAL of 10^{-6}	25
D. 	27
IX. A Person with Specialized Skills in Microbiology Would Have Been Motivated to Use Lam’s EtO Method to Achieve a SAL of 10^{-6} , and Would Have a Reasonable Expectation of Success	29
X. DECLARATION	35

I. INTRODUCTION

1. I have been retained by Petitioner Regeneron Pharmaceuticals, Inc. ("Petitioner" or "Regeneron"), as an independent expert witness in the above-captioned *inter partes* review ("IPR"), in which Regeneron has requested that the U.S. Patent and Trademark Office cancel as unpatentable all claims of U.S. Patent No. 9,220,631 ("the '631 patent") (Ex. 1001).

2. This declaration sets forth my analyses and opinions based on my knowledge, experience, and the materials I have considered.

II. QUALIFICATIONS AND COMPENSATION

3. I have a M.B.A. in Pharmaceutical Studies from Fairleigh Dickinson University, a M.S.Ch.E. from the Polytechnic Institute of New York, and a B.E.Ch.E. from Pratt Institute.

4. I have over fifty years of management experience in pharmaceutical manufacturing, pharmaceutical process, pharmaceutical process engineering, technical services and research and development. Since 1991, I have been the President of Agalloco & Associates, which provides to the pharmaceutical, biotechnology, and medical device industry a wide range of technical services such as process and product validation, sterilization, aseptic processing, processing, isolation technology, sterility assurance, compliance and facility design.

5. Prior to 1991, I was Director of Validation and Technology at Bristol-Myers Squibb; Director of Worldwide Validation and Automated Technology and Pharmaceutical Engineering; Department Manager at Bristol-Myers Squibb, and held a number of other positions, including Engineering Project Manager and Senior Production Supervisor at Pfizer Pharmaceuticals.

6. As Director of Validation and Technology at Bristol-Myers Squibb, I directed validation, automation and technical documentation activities and served as an important technical resource for worldwide pharmaceutical manufacturing. I was an active participant on product introduction and facility upgrade task forces. As Director of Worldwide Validation and Automated Technology at Bristol-Myers Squibb, I was responsible for facilities in 27 countries around the world and served as a major technical resource for facility design, facility start-up, sterilization, aseptic processing, validation and automation. I participated actively on major product, process, facility and equipment projects, directed the validation and automation phases of a \$25 million expansion of existing parenteral facility in New Brunswick, and provided major support to sterile bulk manufacturing. As head of the Validation department at Squibb New Brunswick, I was responsible for validation of all processes at the site including various sterilization processes. I also led the validation effort for a \$60 million parenteral facility.

7. In previous positions, I provided validation expertise for sterile facilities, acted as a spokesperson for validation to the Food and Drug Administration (“FDA”) and other regulatory agencies, managed production operations for sterile and oral liquid and powder products, and had major areas of responsibility including cost control, cost reduction, Current Good Manufacturing Practice (“CGMP”) compliance, scheduling, equipment selection, and process trouble shooting.

8. In addition to my work experience, I have many years of experience participating in professional organizations, and pharmacopoeias relating to sterilization and sterility assurance for pharmaceuticals and medical devices, including microbiology as it relates to sterilization. For example, I have been an active member of the United States Pharmacopoeia (“USP”) Microbiology Expert Committee since 2005, and the lead author on the comprehensive revision of USP <1211> *Sterilization & Sterility Assurance of Compendial Items*. The new USP content (Chapters <1211> *Sterility Assurance* and <1229> *Sterilization*) includes substantially expanded content addressing the full range of sterilization processes and means for the aseptic processing for drugs and medical devices. In addition, I have led and participated in the development of numerous sterilization and aseptic processing industry guidance documents as a member of the Parenteral Drug Association. I have been a member of the Parenteral Drug Association since 1980

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.